Date of this Version
Genomic testing in patients with early-stage breast cancer is associated with decreased use of chemotherapy and lower costs in younger patients, and slightly increased use of chemotherapy and higher costs in older patients. Genomic testing in actual practice may “rule out” chemotherapy in younger women, and “rule in” chemotherapy in older women.
See Original Study
This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 License.
personalized medicine and genomics, medical decision making
View On LDI Website
Date Posted: 09 December 2016